Allowing a higher volume of small-n early stage trials, the focus of this essay, is a rare “win-win” for both public health and scientific progress. For patients, it transforms a terminal diagnosis from a closed door into a “chance at a cure,” providing legal, supervised access to cutting-edge medicine that currently sits idle in labs. For researchers and society, it unclogs the drug discovery funnel; by lowering the barrier to entry for new ideas, we ensure that the next generation of mRNA, peptide and AI-driven therapies are tested in humans years sooner, ultimately accelerating the arrival of universal cures for everyone.
FT Weekend newspaper delivered Saturday plus complete digital access.
，更多细节参见下载向日葵远程控制 · Windows · macOS · Linux · Android · iOS
headers Map(String, String),
// use gRPC exporter with TLS and metadata headers for SigNoz cloud
04:36, 8 марта 2026Мир